| Filed On | Filing |
|---|---|
| 09 Nov 2026 | 10-Q |
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
– Focus development efforts on tagmokitug/toripalimab as a potential best-in-disease treatment for esophageal cancer with plans for expedited development – |
| 29 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
-1L ESCC confirmed ORR of 75% irrespective of PD-L1 status, confirmed ORR of 100% for PD-L1- positive, in evaluable patients- |
| 28 Aug 2026 |
8-K: Other Events
Coherus Oncology, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows: |
| 28 Aug 2026 | 424B5 |
| 28 Aug 2026 | 424B3 |
| 17 Aug 2026 |
8-K: Regulation FD Disclosure; Other Events
THIS CONTINGENT VALUE RIGHTS AGREEMENT (this “Agreement”), dated as of August 17, 2026, is entered into by and between Coherus Oncology, Inc., a Delaware corporation (the “Company”), and Equiniti Trust Company, LLC, a New York limited li... |
| 17 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +1 more
Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a... |
| 05 Aug 2026 | S-8 |
| 05 Aug 2026 | 10-Q |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
– LOQTORZI® net revenue of $13.6 million in Q2 2026, up 15% over Q1 – |
| 27 Jul 2026 | SCHEDULE 13G |
| 15 Jun 2026 |
8-K: Changes in Registrant's Certifying Accountant
We have read Item 4.01 of Form 8-K dated June 12, 2026, of Coherus Oncology, Inc. and are in agreement with the statements contained in the first, second, third and fourth paragraphs on page 1 therein. We have no basis to agree or disagr... |
| 09 Jun 2026 |
Form 4: Satvat Ali J., Director
Received 30,000 shares as a grant or award · Granted 60,000 Stock Option (Right to Buy) |
| 09 Jun 2026 |
Form 4: Karachun Rita A, Director
Received 30,000 shares as a grant or award · Granted 60,000 Stock Option (Right to Buy) |
| 09 Jun 2026 |
Form 4: Newcomer Lee Nisley, Director
Received 30,000 shares as a grant or award · Granted 60,000 Stock Option (Right to Buy) |
| 09 Jun 2026 |
Form 4: Ryan Michael Lee, Director
Received 30,000 shares as a grant or award · Granted 60,000 Stock Option (Right to Buy) |
| 09 Jun 2026 |
Form 4: O'Donnell-Tormey Jill, Director
Received 30,000 shares as a grant or award · Granted 60,000 Stock Option (Right to Buy) |
| 09 Jun 2026 |
Form 4: Wahlstrom Mats, Director
Received 30,000 shares as a grant or award · Granted 60,000 Stock Option (Right to Buy) |
| 09 Jun 2026 |
Form 4: Newton Charles W., Director
Received 30,000 shares as a grant or award · Granted 60,000 Stock Option (Right to Buy) |
Loading...